These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3683020)

  • 1. Aspects for bioavailability and bioequivalence revision: possible implications on clinical pharmacology.
    Ritschel WA
    Methods Find Exp Clin Pharmacol; 1987 Jul; 9(7):453-9. PubMed ID: 3683020
    [No Abstract]   [Full Text] [Related]  

  • 2. Aspects of bioavailability and bioequivalence revision: possible implications on clinical pharmacology.
    Glasser AC
    Methods Find Exp Clin Pharmacol; 1987 Jul; 9(7):449-52. PubMed ID: 3683019
    [No Abstract]   [Full Text] [Related]  

  • 3. Bioavailability and bioequivalence requirements: abbreviated applications. Final Rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Dec; 67(244):77668-75. PubMed ID: 12492102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
    Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bioequivalence of solid drug preparation].
    Ejima A
    Eisei Shikenjo Hokoku; 1982; (100):1-20. PubMed ID: 6897833
    [No Abstract]   [Full Text] [Related]  

  • 6. Bioavailability and bioequivalence requirements in the European community.
    Rauws AG
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():519-32. PubMed ID: 1820933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles.
    Rajaram L; Roy SK; Skerjanec A
    Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic batch certification and bioequivalence.
    DeSante KA; DiSanto AR; Chodos DJ; Stoll RG
    JAMA; 1975 Jun; 232(13):1349-51. PubMed ID: 1173399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability and bioequivalence: an FDA regulatory overview.
    Chen ML; Shah V; Patnaik R; Adams W; Hussain A; Conner D; Mehta M; Malinowski H; Lazor J; Huang SM; Hare D; Lesko L; Sporn D; Williams R
    Pharm Res; 2001 Dec; 18(12):1645-50. PubMed ID: 11785681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations for metabolite pharmacokinetic data in bioavailability/bioequivalence assessments. Overview of the recent trends.
    Srinivas NR
    Arzneimittelforschung; 2009; 59(4):155-65. PubMed ID: 19517891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levothyroxine dosage and the limitations of current bioequivalence standards.
    Hennessey JV
    Nat Clin Pract Endocrinol Metab; 2006 Sep; 2(9):474-5. PubMed ID: 16957756
    [No Abstract]   [Full Text] [Related]  

  • 12. Harmonization of bioavailability and bioequivalence requirements.
    McGilveray IJ; Ormsby E
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():533-40. PubMed ID: 1820935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing individual bioequivalence using the structural equation model.
    Carrasco JL; Jover L
    Stat Med; 2003 Mar; 22(6):901-12. PubMed ID: 12627408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence/bioavailability retention samples.
    Ransom C
    Qual Assur; 1993; 2(1-2):42-3. PubMed ID: 8156218
    [No Abstract]   [Full Text] [Related]  

  • 15. Bioequivalence; its history, practice, and future.
    Midha KK; McKay G
    AAPS J; 2009 Dec; 11(4):664-70. PubMed ID: 19806461
    [No Abstract]   [Full Text] [Related]  

  • 16. Dosage form performance: a major factor in clinical medicine.
    Dittert LW
    Conn Med; 1976 May; 40(5):333-7. PubMed ID: 776529
    [No Abstract]   [Full Text] [Related]  

  • 17. The significance of pharmacodynamic measurements in the assessment of bioavailability and bioequivalence of psychotropic drugs using CEEG and dynamic brain mapping.
    Itil TM; Itil KZ
    J Clin Psychiatry; 1986 Sep; 47 Suppl():20-7. PubMed ID: 3528132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability and bioequivalence requirements; abbreviated applications; proposed revisions--FDA. Proposed rule.
    Fed Regist; 1998 Nov; 63(223):64222-8. PubMed ID: 10339051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Requirements for submission of bioequivalence data; final rule. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(11):2849-62. PubMed ID: 19385107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.